• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估非酒精性脂肪性肝病患者肝脂肪变的控制衰减参数与磁共振成像质子密度脂肪分数的关系。

Relationship between controlled attenuated parameter and magnetic resonance imaging-proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD.

机构信息

Institute of Liver DiseasesShuguang Hospital Affiliated to Shanghai University of Traditional Chinese MedicineShanghaiChina.

Shanghai Key Laboratory of Traditional Chinese Clinical MedicineShanghaiChina.

出版信息

Hepatol Commun. 2022 Aug;6(8):1975-1986. doi: 10.1002/hep4.1948. Epub 2022 Apr 5.

DOI:10.1002/hep4.1948
PMID:35384367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9315137/
Abstract

We used cross-sectional and longitudinal studies to comprehensively compare hepatic steatosis measurements obtained with magnetic resonance imaging-proton density fat fraction (MRI-PDFF) and controlled attenuated parameter (CAP) in hepatic steatosis in adults with nonalcoholic fatty liver disease (NAFLD). A total of 185 participants with NAFLD and 12 non-NAFLD controls were recruited. CAP and MRI-PDFF data were collected at baseline from all participants and from 95 patients included in the longitudinal study after 24 weeks of drug or placebo intervention. Pearson correlation, linear regression, and piecewise linear regression analyses were used to evaluate the relationship between the two modalities. Linear analysis suggested a positive correlation between CAP and MRI-PDFF (r = 0.577, p < 0.0001); however, piecewise linear regression showed no correlation when CAP was ≥331 dB/m (p = 0.535). In the longitudinal study, both the absolute and relative change measurements were correlated between the two modalities; however, the correlation was stronger for the relative change (relative r = 0.598, absolute r = 0.492; p < 0.0001). Piecewise linear regression analysis revealed no correlation when CAP was reduced by more than 53 dB/m (p = 0.193). Conclusions: We found a correlation between CAP and MRI-PDFF measurements for grading hepatic steatosis when CAP was <331 dB/m. While the measured absolute change and relative change were correlated, it was stronger for the relative change. These findings have implications for the clinical utility of CAP or MRI-PDFF in the clinical diagnosis and assessment of NAFLD.

摘要

我们使用横断面和纵向研究,全面比较磁共振成像质子密度脂肪分数(MRI-PDFF)和受控衰减参数(CAP)在非酒精性脂肪性肝病(NAFLD)成人肝脂肪变性中的测量结果。共招募了 185 名 NAFLD 患者和 12 名非 NAFLD 对照组。所有参与者在基线时均采集 CAP 和 MRI-PDFF 数据,95 名患者在药物或安慰剂干预 24 周后纳入纵向研究。采用 Pearson 相关、线性回归和分段线性回归分析评估两种方式之间的关系。线性分析表明 CAP 和 MRI-PDFF 之间存在正相关(r=0.577,p<0.0001);然而,当 CAP≥331 dB/m 时,分段线性回归显示无相关性(p=0.535)。在纵向研究中,两种方式的绝对和相对变化测量值之间均存在相关性;然而,相对变化的相关性更强(相对 r=0.598,绝对 r=0.492;p<0.0001)。当 CAP 降低超过 53 dB/m 时,分段线性回归分析显示无相关性(p=0.193)。结论:当 CAP<331 dB/m 时,我们发现 CAP 和 MRI-PDFF 测量值之间存在肝脂肪变性分级的相关性。虽然测量的绝对变化和相对变化之间存在相关性,但相对变化更强。这些发现对 CAP 或 MRI-PDFF 在 NAFLD 的临床诊断和评估中的临床应用具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/be96073cd722/HEP4-6-1975-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/0004f898d4bf/HEP4-6-1975-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/adc137644b24/HEP4-6-1975-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/3e54bf5a2f90/HEP4-6-1975-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/da74d5fb9d11/HEP4-6-1975-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/b7e52b2d248c/HEP4-6-1975-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/be96073cd722/HEP4-6-1975-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/0004f898d4bf/HEP4-6-1975-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/adc137644b24/HEP4-6-1975-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/3e54bf5a2f90/HEP4-6-1975-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/da74d5fb9d11/HEP4-6-1975-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/b7e52b2d248c/HEP4-6-1975-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/76a6/9315137/be96073cd722/HEP4-6-1975-g006.jpg

相似文献

1
Relationship between controlled attenuated parameter and magnetic resonance imaging-proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD.评估非酒精性脂肪性肝病患者肝脂肪变的控制衰减参数与磁共振成像质子密度脂肪分数的关系。
Hepatol Commun. 2022 Aug;6(8):1975-1986. doi: 10.1002/hep4.1948. Epub 2022 Apr 5.
2
Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard.前瞻性、同日、直接比较非酒精性脂肪性肝病患者的受控衰减参数与 M 与 XL 探头,以磁共振成像质子密度脂肪分数为标准。
Clin Gastroenterol Hepatol. 2020 Jul;18(8):1842-1850.e6. doi: 10.1016/j.cgh.2019.11.060. Epub 2019 Dec 13.
3
Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis.以 MRI-PDFF 为金标准检测肝脂肪变时的最佳受控衰减参数阈值。
Hepatology. 2018 Apr;67(4):1348-1359. doi: 10.1002/hep.29639. Epub 2018 Feb 19.
4
MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis.磁共振波谱质子密度脂肪分数检测与分级肝脂肪变优于衰减参数控制。
Radiology. 2018 Feb;286(2):547-556. doi: 10.1148/radiol.2017162931. Epub 2017 Sep 15.
5
Usefulness of Controlled Attenuation Parameter in Detecting and Monitoring Hepatic Steatosis with MRI-PDFF as Reference.利用磁共振质子密度脂肪分数成像作为参照标准,评估控制衰减参数在检测和监测肝脏脂肪变性中的作用。
Dig Dis Sci. 2020 May;65(5):1512-1519. doi: 10.1007/s10620-019-05883-1. Epub 2019 Oct 15.
6
Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non-alcoholic fatty liver disease.控制衰减参数在监测非酒精性脂肪性肝病临床相关肝脂肪变性下降中的作用。
Liver Int. 2023 Sep;43(9):1901-1908. doi: 10.1111/liv.15626. Epub 2023 May 30.
7
Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.对肥胖症手术候选者的肝脂肪变性分级及非酒精性脂肪性肝炎检测中瞬时弹性成像、磁共振成像和血清评分的前瞻性比较
JHEP Rep. 2021 Sep 30;3(6):100381. doi: 10.1016/j.jhepr.2021.100381. eCollection 2021 Dec.
8
Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.磁共振成像质子密度脂肪分数作为参考标准的非酒精性脂肪性肝病肝脂肪变性的定量超声射频数据分析。
Korean J Radiol. 2021 Jul;22(7):1077-1086. doi: 10.3348/kjr.2020.1262. Epub 2021 Mar 9.
9
Direct Comparison of Quantitative US versus Controlled Attenuation Parameter for Liver Fat Assessment Using MRI Proton Density Fat Fraction as the Reference Standard in Patients Suspected of Having NAFLD.应用 MRI 质子密度脂肪分数作为参考标准,对疑似患有非酒精性脂肪性肝病的患者进行肝脏脂肪定量超声与受控衰减参数的直接比较。
Radiology. 2022 Jul;304(1):75-82. doi: 10.1148/radiol.211131. Epub 2022 Mar 29.
10
Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease by Using Quantitative US.应用定量超声评估非酒精性脂肪性肝病患者的肝脂肪变
Radiology. 2020 Apr;295(1):106-113. doi: 10.1148/radiol.2020191152. Epub 2020 Feb 4.

引用本文的文献

1
The application performance of MRI-PDFF detection values of different hepatic lobes in diagnosing liver steatosis.不同肝叶MRI-PDFF检测值在诊断肝脂肪变性中的应用性能
Clin Exp Med. 2025 Jun 18;25(1):210. doi: 10.1007/s10238-025-01739-3.
2
Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants: The ALIGN study.一项利用遗传学和非侵入性方法识别高危非酒精性脂肪性肝病(MASLD)参与者的全球新型非侵入性筛查观察性研究的设计与原理:ALIGN研究
Contemp Clin Trials Commun. 2025 Jan 20;44:101437. doi: 10.1016/j.conctc.2025.101437. eCollection 2025 Apr.
3
Construction of a Compound Model to Enhance the Accuracy of Hepatic Fat Fraction Estimation with Quantitative Ultrasound.
构建复合模型以提高定量超声估算肝脂肪分数的准确性。
Diagnostics (Basel). 2025 Jan 17;15(2):203. doi: 10.3390/diagnostics15020203.
4
Exposure-response modeling of liver fat imaging endpoints in non-alcoholic fatty liver disease populations administered ervogastat alone and co-administered with clesacostat.在单独给予ervogastat以及与clesacostat联合给药的非酒精性脂肪性肝病患者群体中,对肝脏脂肪成像终点进行暴露-反应建模。
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):317-330. doi: 10.1002/psp4.13275. Epub 2024 Nov 20.
5
Accuracy of controlled attenuation parameter for liver steatosis in patients at risk for metabolic dysfunction-associated steatotic liver disease using magnetic resonance imaging: a systematic review and meta-analysis.使用磁共振成像评估代谢功能障碍相关脂肪性肝病风险患者肝脏脂肪变性的受控衰减参数准确性:一项系统评价和荟萃分析。
Ann Gastroenterol. 2024 Sep-Oct;37(5):579-587. doi: 10.20524/aog.2024.0910. Epub 2024 Aug 19.
6
A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study.一种基于受控衰减参数的新型评分可准确预测代谢功能障碍相关脂肪性肝病患者的肝脂肪变:一项推导和独立验证研究。
Clin Transl Gastroenterol. 2024 Mar 1;15(3):e00680. doi: 10.14309/ctg.0000000000000680.
7
First-in-human diagnostic study of hepatic steatosis with computed ultrasound tomography in echo mode.肝脏脂肪变性的人体首次诊断研究:回声模式下的计算机超声断层扫描
Commun Med (Lond). 2023 Dec 9;3(1):176. doi: 10.1038/s43856-023-00409-3.
8
The Calculation and Evaluation of an Ultrasound-Estimated Fat Fraction in Non-Alcoholic Fatty Liver Disease and Metabolic-Associated Fatty Liver Disease.非酒精性脂肪性肝病和代谢相关脂肪性肝病中超声估计脂肪分数的计算与评估
Diagnostics (Basel). 2023 Oct 31;13(21):3353. doi: 10.3390/diagnostics13213353.
9
Advancements in Diagnostic and Therapeutic Interventions of Non-alcoholic Fatty Liver Disease: A Literature Review.非酒精性脂肪性肝病诊断与治疗干预的进展:文献综述
Cureus. 2023 Sep 8;15(9):e44924. doi: 10.7759/cureus.44924. eCollection 2023 Sep.
10
Transcriptome Sequencing Reveals Autophagy Networks in Rat Livers during the Development of NAFLD and Identifies Autophagy Hub Genes.转录组测序揭示了 NAFLD 发展过程中大鼠肝脏中的自噬网络,并鉴定了自噬枢纽基因。
Int J Mol Sci. 2023 Mar 29;24(7):6437. doi: 10.3390/ijms24076437.